Ipca Laboratories News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ipca Laboratories Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Ipca Laboratories from all sources in a single place.

Ipca Laboratories Ltd.

22 Dec 2025

1386.20

-3.37%

SAST

Ipca Laboratories Ltd - 524494 - Closure of Trading Window

BSE India

Closure of Trading Window

pdf

Ipca Laboratories Ltd.

05 Dec 2025

1386.20

-3.37%

Company Update

Ipca Laboratories Ltd - 524494 - Inspection Of Company'S Active Pharmaceutical Ingredients (Apis) Manufacturing Facility Situated …

BSE India

Inspection of Company''s Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Tarapur (Palghar-Maharashtra) by US FDA

pdf

Ipca Laboratories Ltd.

03 Dec 2025

1386.20

-3.37%

Emkay predicts strong upside in Ipca Labs shares on India, export growth

Business Standard

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of 1,700 -- a 19 per cent upside from current levels

Ipca Laboratories Ltd. is trading below its 30 day SMA of 1433.0

Ipca Laboratories Ltd.

18 Nov 2025

1386.20

-3.37%

Company Update

Ipca Laboratories Ltd - 524494 - Re-Lodgement Of Transfer Requests Of Physical Shares Report - October …

BSE India

Re-lodgement of transfer requests of physical shares Report - October 2025

pdf

Ipca Laboratories Ltd.

17 Nov 2025

1386.20

-3.37%

Company Update

Ipca Laboratories Ltd - 524494 - Clarification Sought On Volume Movement

BSE India

Clarification sought on Volume Movement

pdf

Ipca Laboratories Ltd.

17 Nov 2025

1386.20

-3.37%

Company Update

Ipca Laboratories Ltd - 524494 - Clarification sought from Ipca Laboratories Ltd

BSE India

The Exchange has sought clarification from Ipca Laboratories Ltd on November 17, 2025, with reference to Movement in Volume.The reply is awaited.

Ipca Laboratories Ltd.

17 Nov 2025

1386.20

-3.37%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Revenues growth a little subdued but margins strongRevenues grew ~9% YoY to 2556.5 crore driven by both domestic formulations and API exports. Domestic formulations grew 8% YoY to 1019 crore, driven by strong traction in pain management but also had some impact on account of GST rate rationalization. Export APIs grew ~45% to 221 crore. Under exports formulations - Branded exports grew ~2% to 145 crore, Institutional exports de-grew 29% YoY to 79.7 crore and generic exports de-grew 6% YoY to 268 crore. EBITDA grew 23.4% YoY to 545 crore while EBITDA margins grew by 257 bps to 21.3% aided...